Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS: Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials. Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331). RESULTS: Dose-proportional exposure of liraglutide up to and including 3.0 mg was confirmed. Body weight and sex influenced exposure of liraglutide 3.0 mg, while age ≥70 years, race, ethnicity and baseline glycaemic status did not. Compared with a reference subject weighing 100 kg, exposure of liraglutide 3.0 mg was 44 % lower for a subject weighing 234 kg (90 % CI 41-47), 41 % higher for a subject weighing 60 kg (90 % CI 37-46), and 32 % higher (90 % CI 28-35) in females than males with the same body weight. Neither injection site nor renal function significantly influenced exposure of liraglutide 3.0 mg (post hoc analysis). CONCLUSION: Population pharmacokinetics of liraglutide up to and including 3.0 mg daily in overweight and obese adults demonstrated dose-proportional exposure, and limited effect of covariates other than sex and body weight. These findings were similar to those previously observed with liraglutide up to 1.8 mg in subjects with type 2 diabetes mellitus. Further analysis of exposure-response relationship and its effect on dose requirements is addressed in a separate publication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Model-derived relationship between liraglutide AUC and dose in obese individuals. Data shown are from the phase II dose-finding trial (Trial 3; Astrup et al. [27]) and represent means and 95 % CI. AUC area under the curve, CI confidence interval, N number of subjects](https://figures.cochat.ai/paper-figures/433237625b1b491da2217032e9ce4f3b/liraglutide-3-0-mg-for-weight-management-a-population-pharmacokinetic-analysis-figure-1.jpg)


![Fig. 4 Exposure distribution (patient frequency) predicted for liraglutide 3.0 mg in overweight/obese subjects with (Trial 2 [6]) and without T2DM (Trial 1 [5]) compared with liraglutide 1.8 mg in subjects with T2DM [26]. AUC area under the curve, T2DM type 2 diabetes mellitus](https://figures.cochat.ai/paper-figures/f78b947d45c647d89392418b9338710d/liraglutide-3-0-mg-for-weight-management-a-population-pharmacokinetic-analysis-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of pharmacokinetic analysis revealed that women had a 32% higher liraglutide exposure than men did at similar weights, establishing the female sex as an independent predictor of successful weight loss [89].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of pharmacokinetic analysis revealed that women had a 32% higher liraglutide exposure than men did at similar weights, establishing the female sex as an independent predictor of successful weight loss [89].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis showed that liraglutide exposure was 32% higher in women than in men of comparable weight, thus identifying the female sex as an independent predictor of weight loss achievement [59].”
From Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“However, it has been suggested that this effect could partly be due to increased drug exposure observed in females.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citationSummary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Blagojevic, M., Jinks, C., Jeffery, A., & Jordan, K. P. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2009.08.010 · Cited by 1,397
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 5×
“Methods Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.”
InfluentialSelf-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“The mechanism for liraglutidemediated weight loss has been shown to involve an increase in hypothalamic satiety signals coupled with a decrease in appetite-stimulating signals, resulting in reduced energy intake [7, 8].”
The impact of obesity on health-related quality-of-life in the general adult US population
Jia, H., & Lubetkin, E. I. (2005) · Journal of Public Health · doi:10.1093/pubmed/fdi025 · Cited by 559
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
Eckel, R. H., Kahn, S. E., Ferrannini, E., Goldfine, A. B., Nathan, D. M., Schwartz, M. W., Smith, R. J., & Smith, S. R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0585 · Cited by 552
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 2×
“The mechanism for liraglutidemediated weight loss has been shown to involve an increase in hypothalamic satiety signals coupled with a decrease in appetite-stimulating signals, resulting in reduced energy intake [7, 8].”
Self-citationTrends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010
Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2411 · Cited by 532
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 2×
“The lower limit of quantification (LLOQ) was 30 pmol L-1 for the ELISAs used in Trials 1 and 2, and 18 pmol L-1 for the ELISA used in the dose-finding trial (Trial 3).”
Obesity and its comorbid conditions
Khaodhiar, L., McCowen, K. C., & Blackburn, G. L. (1999) · Clinical Cornerstone · doi:10.1016/s1098-3597(99)90002-9 · Cited by 403
Social and Psychological Consequences of Obesity
WADDEN, T. A., & STUNKARD, A. J. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-6-1062 · Cited by 345
WEIGHT LOSS: A NOVEL AND EFFECTIVE TREATMENT FOR URINARY INCONTINENCE
SUBAK, L. L., WHITCOMB, E., SHEN, H., SAXTON, J., VITTINGHOFF, E., & BROWN, J. S. (2005) · Journal of Urology · doi:10.1097/01.ju.0000162056.30326.83 · Cited by 314
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Adopted by the 18th WMA General Assembly, H. (2001) · HIV Clinical Trials · doi:10.1310/gtfr-2drx-m6ye-elxr · Cited by 227
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217 · cited 1×
“These findings are consistent with the established pharmacokinetic properties of liraglutide at lower doses [36].”
Self-citationDo metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study
Dahaghin, S., Bierma-Zeinstra, S. M. A., Koes, B. W., Hazes, J. M. W., & Pols, H. A. P. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045724 · Cited by 204
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201
Bray, G. A. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70361-3 · Cited by 172
Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing
Pai, M. P. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.05.010 · Cited by 134
Exposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12639 · Cited by 102
Self-citationPrevalence and Risk Factors for Urinary Incontinence in Overweight and Obese Diabetic Women
Phelan, S., Kanaya, A. M., Subak, L. L., Hogan, P. E., Espeland, M. A., Wing, R. R., Burgio, K. L., DiLillo, V., Gorin, A. A., West, D. S., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0516 · Cited by 79
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
Agersø, H., & Vicini, P. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00073-3 · Cited by 70
New pharmacological approaches for obesity management
Rueda‐Clausen, C. F., Padwal, R. S., & Sharma, A. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.113 · Cited by 61
Confirmatory analysis for phase III population pharmacokinetics
Hu, C., Zhang, J., & Zhou, H. (2009) · Pharmaceutical Statistics · doi:10.1002/pst.403 · Cited by 54
Watson, E., Jonker, D. M., Jacobsen, L. V., & Ingwersen, S. H. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009354996 · Cited by 53
Self-citationNew Pharmacological Treatments for the Management of Obesity
Hurt, R. T., Varayil, J. E., & Ebbert, J. O. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0394-0 · Cited by 39
Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment
Ingwersen, S. H., Khurana, M., Madabushi, R., Watson, E., Jonker, D. M., Thi, T. D. L., Jacobsen, L. V., & Tornøe, C. W. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011430504 · Cited by 35
Self-citationJiang, J., Zhang, J., Jacobsen, L. V., & Hu, P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389468 · Cited by 28
Self-citationIngwersen, S. H., Petri, K. C. C., Tandon, N., Yoon, K.-H., Chen, L., Vora, J. P., & Yang, W. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.001 · Cited by 15
Self-citationLiraglutide in Weight Management.
Pi‐Sunyer, X. (2015) · PubMed · doi:10.1056/nejmc1509759 · Cited by 15
Research works printed but not linked: 1
- Federación Mexicana de Diabetes A.C. COFEPRIS approved the first treatment for chronic management of obesity in Mexico [press release], Feb 2015. Available at: http://fmdiabetes.org/aprueba-la-cofepris-primer-tratamiento-para-el-manejo-cronico-de-la-obesidad-en-mexico/ . Accessed Nov 2015.
Cited by
Sex/gender differences in obesity prevalence, comorbidities, and treatment
Cooper, A. J., Gupta, S. R., Moustafa, A. F., & Chao, A. M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00453-x · Cited by 483
Muscogiuri, G., Verde, L., Vetrani, C., Barrea, L., Savastano, S., & Colao, A. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02196-z · Cited by 164
“In preregistration clinical trials, gender-related differences have also been observed in lira-glutide disposition, as liraglutide exposure was about 32% higher in women than in men, possibly because of more efficient drug degradation in men [47].”
BackgroundAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“With regards to data from preregistration, clinical trials show that liraglutide exposure is about 32% higher in women than in men after adjusting for body weight [102,103]; and different pharmacokinetics have been described with a higher rate of drug degradation in men when compared with women [102,103].”
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“Pharmacokinetic analysis of liraglutide exposure showed 32% higher exposure in women than in men, independent of body weight, suggesting that female sex is an independent factor promoting weight loss [332].”
Metadata
- Authors
- Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Overgaard, Rune V.
- Venue
- Clinical Pharmacokinetics
- Published
- 2016-05-19
- Volume
- 55
- Issue
- 11
- Pages
- 1413-1422
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC5069304
- OpenAlex
- W2398911378
- Cited by
- 64
- References
- 40
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 6 · 2017: 1 · 2016: 1
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk (DK)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, pharmacokinetics, weight management, obesity, overweight, GLP-1 receptor agonists, dose proportionality, body weight, sex differences, covariates, exposure-response relationship, type 2 diabetes, prediabetes
- MeSH terms
- Liraglutide, Adolescent, Adult, Age Factors, Aged, Body Weight, Dose-Response Relationship, Drug, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Models, Biological, Obesity, Prediabetic State, Sex Factors, Overweight, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.